Oliver Luxxe Assets LLC Sells 46,892 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Oliver Luxxe Assets LLC decreased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 48.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,744 shares of the biopharmaceutical company’s stock after selling 46,892 shares during the period. Oliver Luxxe Assets LLC’s holdings in Catalyst Pharmaceuticals were worth $1,563,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of CPRX. Advisory Services Network LLC bought a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at $39,000. Quarry LP acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter worth $40,000. Clearstead Advisors LLC increased its holdings in shares of Catalyst Pharmaceuticals by 192.9% during the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 1,167 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 55.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 630 shares during the period. Finally, Larson Financial Group LLC raised its position in shares of Catalyst Pharmaceuticals by 552.7% during the fourth quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 1,564 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $31.49 on Monday. The company has a 50-day moving average of $31.43 and a 200-day moving average of $27.94. The company has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56.

Analysts Set New Price Targets

Several research firms recently weighed in on CPRX. Stephens set a $32.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Zacks Research lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Finally, Citigroup lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).